Based on these results, six patients received targeted therapy: one patient with a CDK4-amplified tumour (dedifferentiated liposarcoma) received CDK4 inhibitor, two patients with angiosarcoma and high TMB received immune checkpoint inhibitor therapy. The gene discussed is CDK4; the disease is angiosarcoma.